99 results about "Bile Duct Carcinoma" patented technology

The invention relates to a human intrahepatic cholangiocarcinoma cell line with high tumorigenic ability and application thereof. The invention discloses a novel human intrahepatic cholangiocarcinoma cell line which grows stably and has clear quantity of generations and high tumorigenic rate; the human intrahepatic cholangiocarcinoma cell line can form an adenoid tumor in vivo and can be used for in-vivo and in-vitro research on human intrahepatic cholangiocarcinoma; a foundation is laid for constructing an in-vivo animal model, disclosing a tumor malignant progression mechanism, screening related biomarkers and developing novel intrahepatic cholangiocarcinoma resisting medicines.

Provided are vesicles derived from bacteria belonging to the genus Micrococcus, a composition and a use thereof, wherein the vesicles and the composition comprising the same may be effectively used for the development of a method of diagnosing gastric cancer, pancreatic cancer, cholangiocarcinoma, breast cancer, ovarian cancer, bladder cancer, myocardial infarction, cardiomyopathy, atrial fibrillation, variant angina, chronic obstructive pulmonary disease (COPD), dementia, or diabetes.

Disclosed herein are a pharmaceutical composition for inhibiting the growth or metastasis of cholangiocarcinoma, comprising a L1CAM activity inhibitor or expression suppressor and a treatment method using the composition. This is based on the finding that L1CAM is overexpressed on cholangiocarcinoma and plays an important role in the growth and metastasis of cholangiocarcinoma and the mortality of cholangiocarcinoma patients increases as the expression rate of L1CAM increases. Also, antibodies inhibitory of the activity of L1CAM, or siRNAs suppressing the expression of L1CAM, are found to reduce the growth and invasion of cholangiocarcinoma cells. Mouse monoclonal antibodies, recognizing the L1CAM protein on the cholangiocarcinoma cell surface and binding specifically to cholangiocarcinoma tissues, or siRNAs, antisense oligonucleotides or shRNAs, may be useful in the treatment of cholangiocarcinoma by inhibiting the growth, invasion and migration of cholangiocarcinoma cell.

Biological implants have an electroplated surface wherein a substantial portion of the electroplated surface is covered with dendrites. The dendrites assist in maintaining the implant in location. When the metal is a radioactive metal or the surface of the electroplated is coated with a radioactive material, the dendrites increase surface area thereby increasing radiation dosage and further extend the radioactive surface farther away from the surface of the implant, further enhancing radioactive emission. This is particularly useful for a cholangiocarcinoma stent which can be implanted into the biliary stent to treat cholangiocarcinoma.

The invention discloses the application of protein MUC13 in the preparation of reagents for diagnosing intrahepatic cholangiocarcinoma. The present invention utilizes the advantages of high-throughput and rapid analysis of the human proteome chip to analyze the relevant serum of patients with intrahepatic cholangiocarcinoma, compare the differences between the samples of intrahepatic cholangiocarcinoma patients and healthy people in a short period of time, and find that the MUC13 protein The expression level of MUC13 in patients with intrahepatic cholangiocarcinoma was significantly higher than that in healthy people, suggesting that MUC13 protein can be used as a candidate serum biomarker for intrahepatic cholangiocarcinoma for early diagnosis and effective treatment of intrahepatic cholangiocarcinoma. Tests have proved that the serum marker MUC13 provided by the present invention has a specificity of 90%, a sensitivity of 91.67%, and has the characteristics of high specificity and high sensitivity. Further, the present invention also provides a sensitive, safe, reliable, and easy-to-operate commercial kit, which can be used to qualitatively measure the level of anti-MUC13 IgG antibody in human serum, which is helpful for the early diagnosis of intrahepatic cholangiocarcinoma.

The present invention relates to a method for diagnosing cholangiocarcinoma via a bacterial metagenomic analysis, and more specifically, to a method for diagnosing cholangiocarcinoma by performing a bacterial metagenomic analysis using a sample derived from a subject so as to analyze the content increase / decrease of extracellular vesicles derived from specific bacteria. The extracellular vesicles,secreted from bacteria present in the environment, may directly affect the incidence of cancer by being absorbed in the human body, and early diagnosis of cholangiocarcinoma before symptoms appear isdifficult, and thus the efficient treatment thereof is difficult. Thus, by preemptively predicting the risk for the onset of cholangiocarcinoma via the metagenomic analysis, according to the presentinvention, of extracellular vesicles derived from bacteria using a sample derived from a human body, cholangiocarcinoma risk groups may be diagnosed and predicted at an early stage so as to delay thetime of onset or prevent the onset of cholangiocarcinoma through proper care, and early diagnosis may be possible even after the onset, and thus the incidence rate of cholangiocarcinoma may be lowered, and a therapeutic effect therefor may be increased.

The invention discloses an observation device for the proliferation of cholangiocarcinoma cells, which includes a lifting slider, a self-rotating component, an observation mirror and a culture dish arrangement component, wherein the lifting slider is provided with the self-rotating component, and the self-rotating component is arranged on the lifting slider. The output end of the rotating assembly can rotate around its vertical axis of rotation, and the output end of the self-rotating assembly is provided with an observation mirror; the bottom of the observation mirror is provided with at least two groups of culture dish arrangement assemblies, and the two groups of culture dishes The dish arrangement assemblies are distributed on the same circumference, and the center of the circle is located on the vertical axis of rotation of the self-rotating assembly; the culture dish arrangement assemblies at least include a position adjustment assembly, and the position adjustment assembly can hold the culture dish or drive The petri dish performs self-rotating motion; the observation mirror at least includes an objective lens, and when the position adjustment assembly is located below the objective lens, the vertical line where the observation center of the objective lens is located is the vertical line of the self-rotating motion of the petri dish. Axis misalignment setting.

The invention relates to the use of pharmaceutical compositions of the SGLT2 inhibitor, remogliflozin etabonate, to treat primary sclerosing cholangitis (PSC). Methods and compositions associated with the invention can improve or maintain clinical outcomes of PSC symptoms, such as ascites accumulation, hepatic encephalopathy, development of varices, jaundice, variceal bleeding, cholangiocarcinoma, hepatocellular carcinoma, evidence of cirrhosis, and colorectal cancer.